Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA386617
Max Phase: Preclinical
Molecular Formula: C56H77N17O12S2
Molecular Weight: 1244.47
Molecule Type: Protein
Associated Items:
ID: ALA386617
Max Phase: Preclinical
Molecular Formula: C56H77N17O12S2
Molecular Weight: 1244.47
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]cn2)NC(=O)[C@H](CCC(=O)O)NC1=O
Standard InChI: InChI=1S/C56H77N17O12S2/c1-31(74)65-43-28-86-87-29-44(54(84)68-39(15-7-8-20-57)55(85)73-22-10-17-45(73)47(58)77)72-51(81)41(24-33-26-63-36-14-6-5-13-35(33)36)70-48(78)37(16-9-21-62-56(59)60)66-50(80)40(23-32-11-3-2-4-12-32)69-52(82)42(25-34-27-61-30-64-34)71-49(79)38(67-53(43)83)18-19-46(75)76/h2-6,11-14,26-27,30,37-45,63H,7-10,15-25,28-29,57H2,1H3,(H2,58,77)(H,61,64)(H,65,74)(H,66,80)(H,67,83)(H,68,84)(H,69,82)(H,70,78)(H,71,79)(H,72,81)(H,75,76)(H4,59,60,62)/t37-,38+,39+,40+,41+,42-,43+,44+,45-/m1/s1
Standard InChI Key: FMZPUKORONKIFF-DTOBWKGJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1244.47 | Molecular Weight (Monoisotopic): 1243.5379 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Cody WL, Wilkes BC, Muska BJ, Hruby VJ, Castrucci AM, Hadley ME.. (1984) Cyclic melanotropins. 5. Importance of the C-terminal tripeptide (Lys-Pro-Val)., 27 (9): [PMID:6332195] [10.1021/jm00375a018] |
Source(1):